BTAI vs TELA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BTAI shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
TELA exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a catastrophic ROE of -223.35%. While the company maintains a strong gross margin (68.17%) and modest revenue growth (18.2%), these are completely offset by extreme leverage (Debt/Equity of 9.13) and a consistent 25-quarter history of negative earnings. The stock's 5-year price collapse of 95.4% reflects a fundamental loss of investor confidence that is not countered by any meaningful insider buying or operational profitability.
Compare Another Pair
Related Comparisons
BTAI vs TELA: Head-to-Head Comparison
This page compares BioXcel Therapeutics, Inc. (BTAI) and TELA Bio, Inc. (TELA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.